Amgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine

Collaboration Designed to Maximize the Launch of First-in-Class Program and to More Effectively Reach People Living With Migraine THOUSAND OAKS, Calif., April 24, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced an expanded commercial collaboration with Novartis for erenumab, which is being investigated for the prevention of migraine. This expanded commercial collaboration builds on a global neuroscience collaboration in Alzheimer's disease and migraine established in 2015 between Novartis and Amgen. This expanded collaboration leverages Novartis' strong and established presence in neuroscience to more effectively reach people with migraine. The companies have agreed to combine ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news